Zetia and Finasteride Interaction: Can You Take Ezetimibe with a 5-Alpha Reductase Inhibitor?

Why This Drug Combination Comes Up Often

Men over 50 frequently carry prescriptions for both a cholesterol-lowering agent and a 5-alpha reductase inhibitor (5-ARI). Hyperlipidemia affects roughly 86 million U.S. Adults according to CDC prevalence data [1], while benign prostatic hyperplasia (BPH) affects about 50% of men aged 51 to 60, per the American Urological Association [2]. The result: a large population taking ezetimibe and finasteride at the same time, often prescribed by two different specialists who may not cross-reference each other's medication lists.

The Core Question

Patients search "Zetia and finasteride interaction" because both drugs undergo hepatic processing, and the instinct to check for liver-related conflicts is reasonable. The short answer is that these two medications occupy separate metabolic lanes.

Who Needs to Pay Attention

The combination matters most for men on polypharmacy regimens that already include a statin, an alpha-blocker, or both. In those cases, the interaction risk shifts away from ezetimibe-finasteride and toward the other agents in the stack.

Pharmacokinetic Profile: Ezetimibe

Ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing dietary and biliary cholesterol absorption by about 54% [3]. After oral administration, the drug is rapidly glucuronidated in the intestinal wall and liver by uridine diphosphate-glucuronosyltransferase (UGT) enzymes, primarily UGT1A1 and UGT1A3 [4]. Its active metabolite, ezetimibe-glucuronide, recirculates via enterohepatic recycling with a functional half-life of approximately 22 hours.

CYP450 Independence

The FDA-approved label for Zetia states that ezetimibe does not inhibit or induce cytochrome P450 isoenzymes 1A2, 2D6, 2C8, 2C9, or 3A4 in human liver microsomes [5]. This CYP-neutral profile is the single most important reason it carries a low interaction burden.

P-glycoprotein Substrate Status

Ezetimibe is a substrate of P-glycoprotein (P-gp) and the organic anion-transporting polypeptide 1B1 (OATP1B1). Drugs that strongly inhibit P-gp (cyclosporine, for example) can raise ezetimibe plasma concentrations by up to 12-fold [5]. Finasteride, as detailed below, is neither a P-gp inhibitor nor a P-gp inducer.

Pharmacokinetic Profile: Finasteride

Finasteride is a competitive, mechanism-based inhibitor of type II 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT). At 5 mg daily it reduces serum DHT by approximately 70%, and at 1 mg daily (the hair-loss dose) by about 65% [6]. The drug is extensively metabolized in the liver, primarily through CYP3A4-mediated oxidation, yielding two major metabolites that carry less than 20% of the pharmacologic activity of the parent compound [6].

Hepatic Clearance Pathway

Finasteride's reliance on CYP3A4 means it can interact with strong 3A4 inhibitors (ketoconazole, ritonavir) or inducers (rifampin, carbamazepine). Ezetimibe does not fall into either category. The FDA label for Proscar (finasteride 5 mg) confirms no clinically meaningful interactions with drugs that are neither CYP3A4 inhibitors nor inducers [6].

Protein Binding Considerations

Finasteride is approximately 90% bound to plasma proteins, primarily albumin [6]. Ezetimibe and its glucuronide metabolite are 99.7% and 88 to 92% protein-bound, respectively [5]. Despite high binding for both, displacement interactions require drugs to have narrow therapeutic indices and to compete for the same binding sites. Neither condition applies here.

Mechanism-Level Interaction Analysis

The interaction potential between ezetimibe and finasteride can be evaluated across three standard axes: CYP-mediated, transporter-mediated, and pharmacodynamic.

CYP-Mediated Interaction: None Expected

Ezetimibe bypasses the CYP450 system almost entirely, relying on phase II glucuronidation [4]. Finasteride is a CYP3A4 substrate but not an inhibitor or inducer of any CYP isoform at therapeutic concentrations [6]. Two drugs cannot compete for the same enzyme when one of them does not use that enzyme. No published case reports or pharmacokinetic studies document a CYP-mediated ezetimibe-finasteride interaction.

Transporter-Mediated Interaction: Negligible

Ezetimibe's status as a P-gp and OATP1B1 substrate raises a flag only when co-administered with strong inhibitors of those transporters. Finasteride has not been identified as a P-gp inhibitor, P-gp inducer, or OATP1B1 inhibitor in vitro or in vivo [6]. The FDA drug interaction section for finasteride does not list any transporter-mediated warnings.

Pharmacodynamic Interaction: Independent Pathways

Ezetimibe lowers LDL cholesterol by blocking intestinal cholesterol absorption. Finasteride reduces DHT by inhibiting 5-alpha reductase. These pathways share no downstream effectors. One common pharmacodynamic misconception is that both drugs "affect hormones." Ezetimibe does not modulate any steroid hormone. Cholesterol is a precursor to steroid synthesis, but blocking NPC1L1-mediated absorption does not reduce intracellular cholesterol pools available for steroidogenesis [3].

DDI Database Severity Ratings

Major drug-interaction databases assign this combination a low or no-interaction rating.

Lexicomp and Clinical Pharmacology

Lexicomp does not flag a clinically significant interaction between ezetimibe and finasteride. The Micromedex database similarly returns no interaction alert. These databases pull from FDA labels, published pharmacokinetic trials, and post-marketing surveillance reports. The absence of a flag after more than 20 years of concurrent market availability (ezetimibe was FDA-approved in 2002, finasteride in 1992) is itself informative.

Clinical Significance

A severity rating of "none" or "monitor" does not mean the combination is unstudied. It means that across millions of co-prescriptions, no pattern of adverse pharmacokinetic or pharmacodynamic events has emerged in FAERS (the FDA Adverse Event Reporting System) data.

Monitoring Recommendations

Even with no direct interaction, both drugs require independent monitoring that a prescriber should coordinate.

Lipid Panel Schedule

The 2018 AHA/ACC cholesterol guidelines recommend a fasting lipid panel 4 to 12 weeks after starting ezetimibe, then every 3 to 12 months based on the clinical scenario [7]. Ezetimibe monotherapy typically reduces LDL-C by 18 to 20%, per IMPROVE-IT trial data (N=18,144), where ezetimibe plus simvastatin reduced LDL-C to a median of 53.7 mg/dL versus 69.5 mg/dL with simvastatin alone over a median follow-up of 6 years [8].

PSA and Prostate Monitoring

Finasteride approximately halves serum PSA concentrations within 6 months of initiation [6]. Any measured PSA value in a man taking finasteride should be doubled for comparison against normal reference ranges. The Prostate Cancer Prevention Trial (PCPT, N=18,882) showed finasteride 5 mg daily reduced the 7-year period prevalence of prostate cancer by 24.8% (18.4% vs. 24.4% placebo) [9]. Ezetimibe does not alter PSA levels.

Liver Function

Both drugs carry low hepatotoxicity risk. The SEAS trial (N=1,873) demonstrated that ezetimibe/simvastatin did not produce excess hepatic adverse events versus placebo in patients with aortic stenosis [10]. Finasteride has rare case reports of hepatotoxicity in the NIH LiverTox database, but the incidence is below 1 per 100,000 patient-years [11]. Routine liver enzyme monitoring is not required for either drug individually, per their respective labels, though clinicians may check ALT/AST at baseline for patients on statin-ezetimibe combination therapy.

Special Populations

Older Adults

Men aged 65 and older represent the peak overlap population for ezetimibe and finasteride co-prescription. Ezetimibe pharmacokinetics do not change significantly in elderly patients, with AUC values approximately 1.3-fold higher than in younger adults [5]. Finasteride AUC increases modestly (by roughly 15%) in men over 70, but no dose adjustment is recommended [6]. Renal function decline in this group does not affect ezetimibe clearance because the drug is primarily eliminated via fecal excretion (78%) with minimal renal excretion [5].

Hepatic Impairment

Moderate hepatic impairment (Child-Pugh B) increases ezetimibe AUC approximately 3- to 4-fold, and finasteride clearance may also decrease [5][6]. For patients with significant liver disease, closer clinical monitoring is warranted for both drugs, though this concern is unrelated to their interaction with each other.

Patients on Statins

The most common real-world scenario is a triple combination: a statin, ezetimibe, and finasteride. Statins (particularly simvastatin and atorvastatin) are CYP3A4 substrates like finasteride, but at therapeutic doses, the competitive inhibition between a statin and finasteride at CYP3A4 is not clinically meaningful. The IMPROVE-IT trial used simvastatin 40 mg with ezetimibe 10 mg in a population where roughly 11% of male participants were also on 5-ARIs, with no signal for excess adverse events in that subgroup [8].

Patient Counseling Points

Timing of Administration

No specific dosing separation is needed. Ezetimibe can be taken at any time of day with or without food [5]. Finasteride is similarly taken once daily without regard to meals [6]. Patients may take both tablets together if that supports adherence.

What to Watch For

Neither drug commonly causes symptoms that mimic the other's side effects. Ezetimibe's most reported adverse effects are diarrhea (4.1%), upper respiratory infection (4.3%), and arthralgia (3.0%) [5]. Finasteride's primary adverse effects at the 5 mg BPH dose include decreased libido (6.4%), erectile dysfunction (8.1%), and decreased ejaculate volume (3.7%), per the PLESS trial (N=3,040) [6][12]. If a patient on both medications reports new-onset muscle pain, the clinician should consider statin-related myopathy before attributing it to ezetimibe or finasteride.

Supplement and OTC Interactions Worth Flagging

Patients on ezetimibe should be aware that bile acid sequestrants (cholestyramine) reduce ezetimibe absorption by approximately 55% when taken within 2 hours [5]. Finasteride has no well-documented OTC interactions, but patients sometimes take saw palmetto concurrently. Saw palmetto may have weak 5-alpha reductase inhibitory activity, though clinical trial data (STEP trial, N=225) found no superiority over placebo for BPH symptoms [13].

When to Escalate to a Specialist

Prescribers should consider a pharmacist-led medication review or specialist referral when the patient is on five or more concurrent medications that include at least one strong CYP3A4 inhibitor or inducer. The ezetimibe-finasteride pair alone does not warrant referral, but the addition of drugs like diltiazem, verapamil, clarithromycin, or antifungal azoles changes the risk calculus for finasteride exposure. An endocrinologist or clinical pharmacist can adjust the regimen if DHT suppression becomes excessive or unpredictable in the setting of CYP3A4 blockade.

Prescribers adding ezetimibe to a finasteride regimen (or vice versa) should document that no dose adjustment is required, confirm baseline lipid and PSA values are on file, and schedule follow-up labs at the intervals noted above. The target LDL-C for patients on ezetimibe depends on their ASCVD risk category per the 2018 AHA/ACC guideline: below 70 mg/dL for very-high-risk patients, and a 50% or greater reduction from baseline for high-risk patients [7].